Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.

Tytuł :
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Autorzy :
Knauf W; Onkologische Gemeinschaftspraxis, Frankfurt am Main, Germany.
Abenhardt W
Dörfel S
Meyer D
Grugel R
Münz M
Hartmann H
Marschner N
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2015 Mar; Vol. 33 (1), pp. 15-22. Date of Electronic Publication: 2014 Apr 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Original Publication: Oxford, England : Wiley-Blackwell, c1983-
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Registries/*statistics & numerical data
Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Bendamustine Hydrochloride ; Chlorambucil/administration & dosage ; Cyclophosphamide/administration & dosage ; Female ; Germany ; Hematology/methods ; Hematology/statistics & numerical data ; Humans ; Male ; Nitrogen Mustard Compounds/administration & dosage ; Office Visits/statistics & numerical data ; Prednisone/administration & dosage ; Prospective Studies ; Rituximab ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
References :
N Engl J Med. 2000 Dec 28;343(26):1910-6. (PMID: 11136261)
Blood. 2006 Feb 1;107(3):859-61. (PMID: 16223776)
Lancet. 2007 Jul 21;370(9583):230-239. (PMID: 17658394)
Blood. 2008 Jun 15;111(12):5446-56. (PMID: 18216293)
J Clin Oncol. 2008 Nov 1;26(31):5094-100. (PMID: 18711173)
Blood. 2009 Sep 3;114(10):2044-50. (PMID: 19553638)
Blood. 2009 Oct 15;114(16):3382-91. (PMID: 19605849)
J Clin Oncol. 2009 Sep 10;27(26):4378-84. (PMID: 19652068)
Lancet. 2010 Oct 2;376(9747):1164-74. (PMID: 20888994)
Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4. (PMID: 21908504)
Br J Haematol. 2012 Oct;159(1):67-77. (PMID: 22861163)
J Clin Oncol. 2012 Sep 10;30(26):3209-16. (PMID: 22869884)
Leuk Lymphoma. 2013 Aug;54(8):1821-2. (PMID: 23631654)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Cancer. 1981 Jul 1;48(1):198-206. (PMID: 7237385)
Cancer. 1977 Aug;40(2):855-64. (PMID: 890666)
Contributed Indexing :
Keywords: Germany/epidemiology; ambulatory care; chronic lymphocytic leukaemia; drug therapy/statistical and numerical data; registries
Substance Nomenclature :
0 (Antibodies, Monoclonal, Murine-Derived)
0 (Nitrogen Mustard Compounds)
18D0SL7309 (Chlorambucil)
4F4X42SYQ6 (Rituximab)
8N3DW7272P (Cyclophosphamide)
981Y8SX18M (Bendamustine Hydrochloride)
FA2DM6879K (Vidarabine)
P2K93U8740 (fludarabine)
VB0R961HZT (Prednisone)
Entry Date(s) :
Date Created: 20140416 Date Completed: 20150616 Latest Revision: 20190108
Update Code :
20210210
PubMed Central ID :
PMC4406436
DOI :
10.1002/hon.2139
PMID :
24733536
Czasopismo naukowe
Various treatment options exist for patients with chronic lymphocytic leukaemia (CLL). Clinical registries provide insight into routine treatment and identify changes in treatment over time. The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B-cell neoplasm as administered by office-based haematologists in Germany. Data on patient and tumour characteristics, co-morbidities, systemic treatments, and outcome parameters are recorded. Eight hundred and six patients with CLL were recruited between May 2009 and August 2013. At the start of first-line treatment, median age was 71 years, 64% were male, and 44% had a Binet stage C disease. The most frequently used first-line/second-line regimens were bendamustine + rituximab (BR, 56%/55%), fludarabine + cyclophosphamide + rituximab (FCR, 22%/11%), and bendamustine (B, 5%/9%). Chlorambucil was used in only 7% (first-line) and 6% (second-line) of patients. Patients treated with FCR were younger and healthier than patients treated with BR. Overall, 91% of first-line treatments were successful (40% complete response). Real-life patient populations differ considerably from patients treated in randomized controlled trials. BR and FCR dominate the first-line and second-line treatments of CLL by office-based haematologists in Germany. Future analysis will investigate progression-free and overall survival times.
(© 2014 The Authors. Hematological Oncology Published by John Wiley & Sons, Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies